
Publication|Articles|April 11, 2024
An Evolving Treatment Paradigm: ADCs in Non–Small Cell Lung Cancer
ON FEBRUARY 3, 2024, a select multidisciplinary group of physicians that included surgeons, radiation oncologists, and medical oncologists from academic and community practices participated in a live workshop to discuss current practices and recent updates on ADCs for the treatment of patients with NSCLC. A discussion moderated by Ticiana Leal, MD, provided perspectives and insights on approved and emerging ADCs in NSCLC including key clinical trial data on ADC efficacy and safety, treatment selection, and strategies to manage associated adverse events (AEs). Leal also presented patient cases for discussion.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma
2
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
3
Outcomes With Bridging Therapy Correlate With Cilta-Cel Efficacy, Safety in Multiple Myeloma
4
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
5







































